

Source details

Research Journal of Pharmacy and Technology

Scopus coverage years: 1997, 2005, from 2011 to 2022

Publisher: A and V Publication

ISSN: 0974-3618 E-ISSN: 0974-360X

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Medicine: Pharmacology (medical)

Source type: Journal

CiteScore 2021
1.3

SJR 2021
0.234

SNIP 2021
0.618

- [View all documents >](#)
- [Set document alert](#)
-  [Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology ✕

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 v

$$1.3 = \frac{4,996 \text{ Citations 2018 - 2021}}{3,865 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 i

$$1.2 = \frac{4,646 \text{ Citations to date}}{3,750 \text{ Documents to date}}$$

Last updated on 05 January, 2023 • Updated monthly

CiteScore rank 2021 i

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#13/30	58th
Pharmacology, Toxicology and Pharmaceutics (miscellaneous)		
Medicine		
Pharmacology	#180/255	29th


[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site !\[\]\(5a351309c3b87e4420622c1f0e57efc0_img.jpg\)](#)

Research Journal of Pharmacy and Technology

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
India  Universities and research institutions in India	Medicine Pharmacology (medical) Pharmacology, Toxicology and Pharmaceutics Pharmacology, Toxicology and Pharmaceutics (miscellaneous)	A and V Publication	47
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	0974360X, 09743618	1997, 2005, 2011-2021	Homepage How to publish in this journal editor.rjpt@gmail.com

SCOPE

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal, devoted to pharmaceutical sciences. The aim of RJPT is to increase the impact of pharmaceutical research both in academia and industry, with strong emphasis on quality and originality. RJPT publishes Original Research Articles, Short Communications, Review Articles in all areas of pharmaceutical sciences from the discovery of a drug up to clinical evaluation. Topics covered are: Pharmaceutics and Pharmacokinetics; Pharmaceutical chemistry including medicinal and analytical chemistry; Pharmacognosy including herbal products standardization and Phytochemistry; Pharmacology: Allied sciences including drug regulatory affairs, Pharmaceutical Marketing, Pharmaceutical Microbiology, Pharmaceutical biochemistry, Pharmaceutical Education and Hospital Pharmacy.


 Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS

options 

1 International Journal of Research in Pharmaceutical IND 47% similarity	2 Journal of Applied Pharmaceutical Science IND 44% similarity	3 Indian Journal of Pharmaceutical Sciences IND 43% similarity	4 Brazilian Journal of Pharmaceutical Sciences BRA 41% similarity	5 Turkish Journal of Pharmaceutical Sciences TUR 40% similarity
---	---	---	--	--



Research Journal of Pharmacy and Technology

Pharmacology (medical)

Q3 best quartile

SJR 2021 0.23

powered by scimagojr.com


← Show this widget in your own website

Just copy the code below and paste within your html code:

`<a href="https://www.scimi`



Explore, visually communicate and make sense of data with our new data visualization tool.



Metrics based on Scopus® data as of April 2022

A **Andi Nafisah** 11 months ago
Is this Journal still in coverage by Scopus in 2022?

reply

H **Hawraa Hamid** 1 year ago
I am a researcher I would publish in this journal

reply



CONTENT

- **Formulation and Evaluation of Expectorant activity of Poly Herbal Cough Syrup from Traditional Medicinal Plant extracts of North East India**
Bijay Sharma, Arnab Bagchi, Sonam Bhutia, Bapi Ray Sarkar, Prosanta Pal..... 949
- **Determination of Anti-tuberculosis activity of *Psychotria sarmentosa*, *Aponogeton crispus* and two species of *Pleurotus* mushrooms**
Jayamini Jayantha, Banukie Jayasuriya, Dilanthi Herath, Sugandhika Suresh, Dhammika Magana-Arachchi..... 954
- **Herbal Antagonism of a Superbug – A Novel Approach**
Nirban Dey, Amit Chakravarty, Paramita Gangopadhyay Bhattacharya..... 961
- **Hematology profile, Nutritional status and Health complaints of Pertamina Fuel Station Operators in Makassar, Indonesia**
Ikhrum Hardi S., Tri Martiana, Merryana Adriani, Suharni..... 966
- **Clinical Evaluation of efficacy of Rasarakta pachak Ghanavati in Hyperlipidaemia (Rasagat sneha vridhhi)**
Khyati B. Rohit, Gunvant H. Yeola, Kalyani P. Nishane, Amol H. Waghmare, D. G. Dipankar..... 971
- **Clinical Applications of Pharmacometabonomics in Neurology: Current Status, Future Perspectives and Challenges**
Omar Yahya Alshargi, Samah Mukhlef Alzaid, Zainab Ibrahim Albahouth, Ammar Ali Jaber, Bodoor Saud Al-Dosari.... 976
- **Formulation and Characterization of Mucoadhesive Microspheres of Aceclofenac**
Kurra Venkata Gopaiah, Palavai Sripal Reddy, Mahesh Namballa..... 981
- ***In vitro* Antioxidant and Antidiabetic activity of Silver Nanoparticles Synthesized using *Catharanthus roseus* leaves**
Deepika E, Santhy KS..... 989
- **CNS Lesions- Case series analysis in a Tertiary Care Hospital**
Sontisulochana, Sunderesh Kamal Chander. U, Vaijayanthi..... 998
- **Formulation and Anti-bacterial Activity Test for Liquid Soap Betel Nut Extract (*Areca catechu* L.) against *Staphylococcus aureus***
Sofi Nurmay Stiani, Linda Susanti, Dimas Danang Indriatmoko..... 1003
- **Synthesis, Characterization and Theoretical Study for certain Copper (II) complexes using Organic Chalcone Schiff bases as Ligands**
Zeyad Khudhur Abdulrazzaq, Abdulkareem Hamad Ayfan..... 1008
- **Investigating the use of Liquisolid Compact Technique for Pioglitazone HCl**
S. Subramanian, V. Monisha..... 1013
- **Study of Toxin ‘Ricinine’ present in *Ricinus communis* by TLC and GC-MS A Forensic Perspective**
Baljeet Yadav, Anu Singla, Pawan Gupta, Saba Rashid..... 1018
- **Development and Validation of Head-Space Gas Chromatographic Method in Tandem with Flame ionized detection for the determination of Residual Solvents in Letermovir API synthesis**
P. Bala Krishnaiah, R.E.M. Prema Chandrika..... 1023
- **Formulation and Evaluation of Ethosomal Gel and Non-ethosomal Gel of *S.grandiflora* Leaves**
Rohan Rajkumar Patekar, Heena Bholaram Choudhary, Sachin Devidas Rede..... 1029

- **Comparison of the effectiveness of Alcohol-Based Handrub with the combination of Chlorhexidine Gluconate, N-Propanol and Hydrogen Peroxide in Dr. Soetomo General Hospital, Surabaya, Indonesia**
Dita Mernita Setyawati, Puspa Wardhani..... 1037
- **Estimation of Synergistic Antioxidant Effect of Methanolic Extracts of Some Medicinal Herbs**
Gurleen Kaur, Srishti Gautam, Poonam Arora, Neelima Dhingra..... 1042
- **Neuroprotective effects of feeding *Centella asiatica* (L) Urb. – Study of hippocampal neurons in pups born to alcohol-fed female Wistar rats**
Mitha KV, Saraswati Jaiswal Yadav, Rashmi K S, Ganaraja Bolumbu..... 1047
- **2-Pyrocatechuic Acid Attenuates Carboplatin Induced Hematological Toxicities in Wistar Rats**
Rohini R. Pujari, Deepti D. Bandawane..... 1053
- **Efficacy and safety of Colistin-Imipenem/Cilastatin combination Therapy for Multidrug-Resistant Gram-Negative Bacteria Infections in Critically Ill Pediatric Patients**
Ahmed S. Mancy, Sara Shaheen, Ayman Albaghdady, Nagwa A. Sabri..... 1059
- **The Anti-leukemic Potential of *Cyclea peltata* as Validated by Phytochemical and Cell Line Studies**
Hemant Devidas Une, Lalita Bansidas Bhagure..... 1064
- **Ketoconazole: A Re-emerging choice for Oral candidiasis in patients with human immunodeficiency virus infection/acquired Immunodeficiency Syndrome**
Dwi Murtiastutik, M. Yulianto Listiawan, Lunardi Bintanjoyo, Afif Nurul Hidayati, Septiana Widyantari, Astindari, Maylita Sari..... 1071
- **Non-targeted screening with LC-HRMS and In-Silico Study on Diabetic activity of ethyl acetate extract of Sanrego (*Lunasia amara* Blanco)**
Adriani Adriani, Noorhamdani Noorhamdani, Tri Ardyati, Sri Winarsih..... 1077
- **Lovastatin Loaded Solid lipid nanoparticles for Transdermal delivery: *In vitro* Characterization**
Dinesh Kumar Gupta, Satish Kumar Sharma, Praveen Kumar Gaur, Alok Pratap Singh..... 1085
- **Plant *Calotropis gigantea*: Management of Diabetic Nephropathy in Experimentally Induced Diabetes in Rats**
Harish Kumar, Sunil Sharma, Neeru Vasudeva..... 1090
- **Preparation and Analysis of Faba Bean pods Agar with identification of *C. neoformans***
Hamzia Ali Ajah, Ekhlass N. Ali, Ali S. Kadhium..... 1097
- **Computational Study on Molecular Structure, UV-Visible and Vibrational Spectra and Frontier Molecular Orbital Analysis of (E)-7-((2-Chloroquinolin-3-yl)methylene)-1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one**
Vishnu A. Adole, Abhijit R. Bukane, Ravindra H. Waghchaure, Rohit S. Shinde, Babu S. Jagdale..... 1101
- **Antioxidant and Antiulcer property of different solvent extracts of *Cassia tora* Linn.**
Lalchand D. Devhare, Niharika Gokhale..... 1109
- **Effect of Amlodipine in Proliferative Retinopathy: Biochemical Estimation and Zebrafish (*Danio rerio*) Modeling**
Ashirbad Nanda, Sai Aparna, Rudra Narayan Sahoo, Arunima Pramanik, Bhargab Satpathy, Subrata Mallick, Debajyoti Das, Manorama Patri..... 1114
- **A Taxonomic Study comparing the two types of Medicinal Leeches available in Iraq**
Islam Khalid, Najah Sobhi Nayyef, Marwan M. Merkhan..... 1119
- **Preliminary Qualitative Phytochemical Analysis and Acute Oral Toxicity Study of Latex of an Ethnomedicinal Plant *Euphorbia fusiformis* Buch.-Ham.Ex D.Don**
Yogita S. Ozarde, Vishnu P. Choudhari 1123
- **VDR Gene Polymorphism and Rheumatoid Arthritis in Egyptian patients**
Samar El-Sayed Mahmoud, Abeer M. El-Shafey, A.T. Keshta..... 1128

[ABOUT JOURNAL \(ABOUTJOURNAL.ASPX\)](#) [CONTACT US \(CONTACTUS.ASPX\)](#)



[\(Home.aspx\)](#)

Research Journal of Pharmacy and Technology

[\(Home.aspx\)](#)

ISSN

0974-360X (Online)

0974-3618 (Print)

[HOME ▾ \(HOME.ASPX\)](#)

[PAST ISSUES \(PASTISSUES.ASPX\)](#)

[EDITORIAL BOARD \(EDITORIALBOARD.ASPX\)](#)

[FOR AUTHORS ▾](#)

[MORE ▾](#)

[NEWS \(NEWS.ASPX\)](#)

[Submit Article \(SubmitArticle.aspx\)](#)

search



EDITOR IN CHIEF



DR. MRS. MONIKA S. DAHARWAL ()

Editor In Chief

A & V Publications, RJPT House, Lokmanya GrihNirman Society, Rohanipuram, In-front of Sector- 1, Pt. Deendayal Upadhyay Nagar, Raipur 492 010. (CG) India

Email: editor.rjpt@gmail.com

[🏠 Home Page \(\)](#)

ASSOCIATE EDITOR



MARWAN MAHMOOD SALEH ()

Associate Editor

Anbar-Ramadi- Habbaniya- 4-4-17

Email: bio.marwan92@gmail.com

[🏠 Home Page \(\)](#)



DHANANJAY BABANRAO DESHMUKH ()

Associate Editor

Ashvin college of pharmacy manchi hill ashvi Bk sangamner Ahmednagar

Email: dhananjaydeshmukh777@gmail.com

[🏠 Home Page \(\)](#)



DR.RER.NAT ARLI ADITYA PARIKES ()

Associate Editor

**ZAIN BAAITY ()**

Syria, Latakia

Email: zein_syria@hotmail.com

[🏠 Home Page \(\)](#)**LAITH AHMED NAJAM ()**

Mosul University, College of Science, Physics Dept., Mosul

Email: Prof.lai2014@gmail.com

[🏠 Home Page \(\)](#)**VEEREN DEWOOLKAR ()**

4824 Washtenaw Ave, Apt C1, Ann Arbor, MI 48108

Email: veerenrx@gmail.com

[🏠 Home Page \(\)](#)**NEERAN OBIED JASIM ()**

University of AL-Qadisiyah college of Pharmacy Iraq

Email: neran.jasim@qu.edu.iq

[🏠 Home Page \(\)](#)**MAHMOUD NAJIM ABID ()**

Mustansiriyah University, College of Science, Department of Chemistry

Email: mahmoudaljibouri@gmail.com

[🏠 Home Page \(\)](#)**NILESH PATEL ()**

B/103,Snehkunj Elegance, Behind Shivalay Parisar Kudasar, Gandhinagar-382421, Gujarat

Email: nilesh33.emcure@gmail.com

[🏠 Home Page \(\)](#)**NEERAN OBIED JASIM ()**

university of AL-Qadisiyah -college of science-Iraq

Email: neran.jasim@qu.edu.iq

[🏠 Home Page \(\)](#)

**MARWAN MAHMOOD SALEH ()**

Anbar-Ramadi- Habbaniya- 4-4-17

Email: ah.marwan_bio@uoanbar.edu.iq

[🏠 Home Page \(\)](#)**PALLAVI LAXMAN PHALKE ()**

Parul University, Limda, Waghodiya. Vadodara-391760, Gujarat India.

Email: falkepallavi@gmail.com

[🏠 Home Page \(\)](#)**DR. ANUP S. HENDRE ()**

Biochemistry Department Krishna Institute of Medical Sciences, Malkapur Karad. Dist-Satara.

Email: anupviews@gmail.com

[🏠 Home Page \(\)](#)**SURENDRA KUMAR GAUTAM ()**

Kamla Nehru Institute of Management & Technology, NH96 Faizabad Bypass Road Faridpur Campus

Email: surendra_bkt95@yahoo.in

[🏠 Home Page \(\)](#)**DR U R RAKSHITH ()**

Dr U R Rakshith Lecturer JSS College of Pharmacy, JSS Academy of Higher Education and Research Shivarathreeswara Nagar, Mysuru-570015 Karnataka , India

Email: urrakshith@jssuni.edu.in

[🏠 Home Page \(\)](#)**RAMU SAMINENI ()**

H.NO-1-123-A; C/O SIVARAMAKRISHNA SAMINENI MANDEPUDI, AMARAVATHI

Email: samineni.ramu@gmail.com

[🏠 Home Page \(\)](#)**DHAVAL PATEL ()**

A-104, Maruti Aamrakunj, Sargasan, Gandhinagar-382421

Email: dhaval.nine@gmail.com

[🏠 Home Page \(\)](#)

**AKHIL NAGAR ()**

R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH

Email: akkipharma23@gmail.com

[🏠 Home Page \(\)](#)**SUNANDAR IHSAN ()**

Kampus Hijau Bumi Tridharma Universitas Halu Oleo Fakultas Farmasi, Jl. H.E.A Mokodompit Anduonuhu, Kendari, Indonesia

Email: sunandarihsan@uho.ac.id

[🏠 Home Page \(\)](#)**ANAS TARIK NAFEI ()**

Baghdad, Qadissiyah Express way

Email: anasalhamdany@yahoo.com

[🏠 Home Page \(\)](#)**DR.KUMARASWAMY GULLAPELLI ()**

STREET NUMBER 4 , BHAVANI NAGAR , NACHARAM, HYDERABAD NACHARAM, Hyderabad, Telangana, pincode: 500076

Email: kumargullapelli001@gmail.com

[🏠 Home Page \(\)](#)**RADHWAN AL-ZIDAN ()**

Almothana district, Mosul, Iraq

Email: radhwan.alzidan@uomosul.edu.iq

[🏠 Home Page \(\)](#)**YAHIA M. MOUALLA ()**

faculty of pharmacy, Tishreen university, Latakia, Syria

Email: yahia.moualla@tishreen.edu.sy

[🏠 Home Page \(\)](#)**SUHAS SURESH AWATI ()**

Assistant Professor, Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digranj, Baganvat, Tal- Miraj, Dist- Sangli, Maharashtra. 416301

Email: awatiss@gmail.com

[🏠 Home Page \(\)](#)

**HANA BAJES ()**

NJ-USA

Email: bajes80@gmail.com
[Home Page \(https://www.atlantic.edu/directory/faculty/bajes-hana.php\)](https://www.atlantic.edu/directory/faculty/bajes-hana.php)
**DR. J. SIVAKUMAR ()**

Assistant Professor, PG Department of Zoology, Guru Nanak College (Autonomous), Velachery, Chennai – 600 042, Tamil Nadu, India

Email: sivakumar.j@gurunanakcollege.edu.in
[Home Page \(https://gurunanakcollege.edu.in/school-of-science\)](https://gurunanakcollege.edu.in/school-of-science)
**DR.V.N.INDULATHA ()**

8/50RC Nagar extension, Othakkalmandapam, Coimbatore, Tamilnadu, India

Email: profindulatha@gmail.com
[Home Page \(https://nchs.nirmalacollege.edu.in\)](https://nchs.nirmalacollege.edu.in)
**RISHIKESH BACHHAV ()**

Anjaneri, Trymbakeshwar

Email: bachhavrss@rediffmail.com
[Home Page \(https://www.sapkalpharmacy.org\)](https://www.sapkalpharmacy.org)


Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal...

[Read more >>> \(AboutJournal.aspx\)](#)

RNI: CHHENG00387/33/1/2008-TC

DOI: 10.5958/0974-360X

0.38

56th percentile

2018
CiteScore

Powered by **Scopus**

https://www.scopus.com/sourceid/21100197160?dgcid=sc_widget_citescore

Research Journal of Pharmacy and Technology

Q3

Pharmacology
(medical)

best quartile

SJR 2021

0.23



powered by scimagojr.com

(<https://www.scimagojr.com/journalsearch.php?q=21100197160&tip=sid&exact=no>)

QUICK LINKS



[SUBMIT ARTICLE \(SUBMITARTICLE.ASPX\)](#)



[AUTHOR'S GUIDELINES \(DOWNLOADS/INSTRUCTIONS_TO_AUTHOR.PDF\)](#)



[PAPER TEMPLATE \(DOWNLOADS/PAPER_TEMPLAT.DOC\)](#)



[COPYRIGHT FORM \(DOWNLOADS/COPYRIGHT TRANSFER FORM.DOCX\)](#)



[CERT. OF CONFLICT OF INTREST \(DOWNLOADS/CERTIFICATE OF CONFLICT OF INTREST.PDF\)](#)



[PROCESSING CHARGES \(CHARGESDETAILS.ASPX\)](#)

RESEARCH ARTICLE

Ketoconazole: A Re-emerging choice for Oral candidiasis in patients with human immunodeficiency virus infection/acquired Immunodeficiency Syndrome

**Dwi Murtiastutik^{1*}, M. Yulianto Listiawan¹, Lunardi Bintanjoyo¹, Afif Nurul Hidayati^{1,2},
Septiana Widyantari¹, Astindari¹, Maylita Sari¹**

¹Department of Dermatology and Venereology, Faculty of Medicine, Universitas Airlangga,
Dr. Soetomo General Hospital, Surabaya 60285, Indonesia.

²Universitas Airlangga Teaching Hospital, Surabaya 60115, Indonesia.

*Corresponding Author E-mail: dwimurtiastutik@yahoo.co.id

ABSTRACT:

Background: The long term use of antifungals for oral candidiasis (OC) in patients with Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) causes some strains to be resistant to certain antifungals. HIV/AIDS are currently most common in men. **Aim:** To evaluate ketoconazole sensitivity on *Candida* species in male HIV/AIDS patients with OC. **Method:** This is an observational descriptive study at the Outpatient Unit and Inpatient Installation of the Infectious Disease Intermediate Care Unit (UPIPI) Dr. Soetomo, Surabaya. Samples were taken from HIV/AIDS male patients with OC using sterile swabs. The smear was cultured in CHROMagar *Candida* incubated at 37°C for 48-72 hours, and Sabouraud Dextrose Agar media for 48 hours at 28°C. Species identification were done using carbohydrate and Cornmeal test. Resistance test was done by disk diffusion method. **Results:** There were 23 research subjects with 40 isolates of *Candida* species growing in culture. The most common species was *C. albicans* in 23(57.5%) isolates, while *Candida non-albicans* were found in 17(42.5%) isolates. The sensitivity test results showed that 34 (85%) isolates were sensitive, while 2(5%) isolates were resistant to ketoconazole. All *C. albicans* (23 [100%]) and most *Candida non-albicans* species (11 [64%]) were sensitive to ketoconazole. **Conclusion:** Ketoconazole can be recommended as a treatment option for OC patients with HIV/AIDS due to the high sensitivity of both *C. albicans* and *non-albicans* to this drug.

KEYWORDS: Ketoconazole, Antifungal agents, Candidiasis, oral, Drug resistance, Fungal, HIV.

INTRODUCTION:

Human's oral cavity contains various types of microorganisms which composition, metabolic activity and pathogenicity are influenced by external and internal factors. Among all fungi, the yeast from genus *Candida* is considered as the most widely found species in the oral cavity.¹⁻² *Candida* species are the main cause of mucocutaneous infections namely oral, esophageal and vulvovaginal candidiasis.

Oral candidiasis (OC) is most frequently found in patients with Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) worldwide.^{1,3-4} Almost 90% of HIV/AIDS patients have experienced OC in the course of their illness. A high viral load and a low number of CD4 T lymphocytes are found in OC patients.⁵⁻⁶ Although OC is caused by various types of *Candida*, *C. albicans* is the most common cause according to Reza's research in Malang in 2017, but some studies revealed an increase in OC caused by *Candida non-albicans* as showed in a study in Surabaya in 2008.⁷⁻⁸

Ketoconazole is a cheap, effective and available antifungal in Indonesia. Besides ketoconazole, topical nystatin or oral fluconazole and itraconazole are also

used as a therapeutic option in OC.⁷ Nystatin, ketoconazole and fluconazole are currently listed as management for OC in the Clinical Practice Guide book of the Department of Dermatology and Venereology in our institution.¹⁰ However, recent research has shown that the sensitivity of *Candida* species to azole antifungals, especially fluconazole, is decreased due to its widespread use.^{1,9} Two factors influence this decrease in fluconazole sensitivity, namely: changes in causative species of OC from *Candida albicans* to non-*albicans* such as *C. glabrata* and *C. krusei* which have intrinsic resistance; and the emergence of resistance to the azole group.¹¹⁻¹⁴ Therefore, ketoconazole is another drug of choice for OC.¹⁰ The objective of this study is to evaluate ketoconazole sensitivity on *Candida* species in male HIV/AIDS patients with OC.

MATERIAL AND METHODS:

Subjects:

This study was conducted with observational descriptive method with the approval of the Health Research Ethics Committee of Dr. Soetomo General Hospital Surabaya. Subjects were recruited by total sampling from HIV/AIDS patients with OC who visited the Outpatient Unit and Inpatient Installation of the Infectious Disease Intermediate Care Unit (UPIPI) Dr. Soetomo, Surabaya from May to July 2019. The inclusion criteria were male, aged 18 years or above, willing to participate in the study and sign informed consent. The exclusion criteria was negative culture result. The demographic data, such as gender, age, occupation, clinical features of candidiasis, including main complaint, location, frequency, history of previous treatment, diagnosis and treatment plan, and HIV status including HIV transmission, time of having HIV, clinical stadium of HIV, amount of absolute CD4, and ARV treatment of the research subjects were documented in the patient's medical record. Sampling was done using sterile swabs. Afterwards, the patients were examined for OC and verified by finding white plaque in the intraoral mucous layer and confirmed by the presence of yeast and hyphae through 10% KOH examination and fungal culture of the oral cavity. Those who were verified as OC were selected for this study.

Clinical isolate:

The smear was cultured in CHROMagar *Candida* incubated at 37°C for 48-72 hours. *Candida* was cultured on Sabouraud Dextrose Agar (SDA) media for 48 hours at 28°C for further examination. Grown *Candida* cultures were subjected to identification tests using the carbohydrate and Cornmeal test methods. After the species was identified, the resistance test was carried out using the diffusion disk method. The sensitivity test results are obtained in the form of the diameter of the inhibition zone. The susceptibility and resistance criteria

of antifungal agents were determined according to the interpretation by Rosco Diagnostica Company. With ketoconazole 10µg/disk, diameter of the inhibition zone of ≥28 mm is interpreted as sensitive, 21-27mm as intermediate and ≤20 as resistant.¹

RESULTS:

This study found 23 HIV/AIDS male patients with OC who fulfilled the inclusion criteria. Demographic profiles of the subjects showed that most of the subjects were young adults aged 18 to 35 years (30%), unemployed (48%), and with education level equivalent to high school (44%). The main complaint from clinical manifestation of OC in this study was found to be in the form of white spots in the oral cavity, found in all subjects of 23 people (100%). Most locations were found on the tongue, also found in all of 23 people (100%). The research subjects who experienced OC for the first time were 11 people (48%). Previous history of systemic and topical antifungal treatment was found in 15 people, 4 of whom had received systemic antifungals and 11 had received topical antifungals. One subject may have the main complaint, multiple location of the disease and a history of more than one antifungal treatment. The most common diagnosis of OC is pseudomembranous candidiasis, found in 19(82%) people, although in one subject can also have several types of OC. Most of the research subjects still received topical nystatin therapy, as much as 18 people (78%) (Table 1).

Table 1. Demographic and clinical features of the research subjects

No.	Features	N	%	
1	Age	Late teenager 18 – 25 years old	3	13
		Early adult 26 – 35 years old	4	17
		Late adult 36 – 45 years old	7	31
		Early elderly 46 – 55 years old	5	22
		Late elderly 56 – 65 years old	4	17
		Geriatrics > 66 years old	0	0
2	Level of education	None	3	13
		Elementary School/Junior High School	7	31
		Senior High School	10	43
		Diploma/Bachelor	3	13
3	Occupation	None	11	48
		Civil Servant	2	9
		Private Employees	9	39
		Students	1	4
4	Main complaint	White spots in oral cavity	23	100
		Red spots in oral cavity	1	4
		Spots and wound in lips' corner	1	4
		Spots or wound with swallowing pain, or burning sensation in throat	4	17
5	Location	Mucous	1	4
		Tongue	23	100
		Lips' corner	1	4
6	Frequency	Recurrent	12	52
		First time	11	48

7	History of previous treatment	Systemic antifungal		
		Yes	4	17
		No	19	83
		Topical antifungal		
8	Diagnosis	Pseudomembranous candidiasis		
		Yes	11	48
		No	12	52
		Hyperplastic plaque candidiasis		
9	Treatment plan	Atrophic candidiasis		
		Yes	1	4
		No	1	4
		Cheilitis candidiasis		
9	Treatment plan	Systemic:		
		Fluconazole	5	22
		Ketoconazole	0	0
		Topical:		
		Nystatin	18	78

One subject can have more than one features.

The HIV/AIDS profiles of the subjects was quite diverse. The most common HIV transmission was through heterosexual intercourse (65%). Most of the subjects were in HIV stages III and IV, as much as 12 people (52%) and 9 people (39%). Patients who received ARV were found in 19 (83%) of the study subjects (Table 2).

From 23 research subjects, 40 isolates of *Candida* were found, because in 10 research subjects there were more

than one type of *Candida* cause. The *C. albicans* species is still the main cause of OC in HIV/AIDS patients in Dr. Soetomo Hospital, which was found in 23 isolates (57.5%), while the non-*albicans* group was found in 17 isolates (42.5%) (Table 3).

Table 2. HIV status of research subjects

No.	HIV Status		N	%
	Category	Group		
1	HIV transmission [‡]	Homosexual	6	26
		Heterosexual/Free sex	13	57
		Bisexual	1	4
		Needle/Tattoo/Transfusion	3	13
2	Time of having HIV	< 1 year	11	48
		1- 3 years	9	39
		> 3 years	3	13
3	Clinical stadium of HIV	Stadium I	0	0
		Stadium II	2	9
		Stadium III	12	52
		Stadium IV	9	39
4	Amount of absolute CD4	> 500 cells/ µL	0	0
		200-500 cells/µL	8	35
		< 200 cells/µL	15	65
5	ARV treatment	Yes	19	83
		No	4	17

One subject can have more than one answers.

Table 3. Identification results of *Candida* species

No	Color of colony in CHROM agar	Urea Hydrolysis	Fermentation						Temp 42-45 C	Microscopic appearance	Identification results	Total	%
			Glu	Lac	Suc	Mal	Gal	Tre					
1	Green	(-)	(+)	(-)	(-)	(+)	(-)	(-)	Grew	Chlamydozoa terminalis, circular blastoconidia forming a unity on the pseudohyphae	<i>Candida albicans</i>	23	57.5
2	Tosca	(-)	(+)	(-)	(-)	(+)	(-)	(-)	Did Not Grow	Chlamydozoa abounds in appearance, in pairs, or in groups. Pseudohyphae and hyphae in the blastoconidia cluster	<i>Candida dubliniensis</i>	0	0.0
3	White	(-)	(+)	(-)	(-)	(-)	(+)	(-)	-	Single blastoconidia form, small unity along the relatively short and curved pseudohyphae. There is a "Giant Cell"	<i>Candida parapsilosis</i>	1	2.5
4	Prussian Blue	(-)	(+)	(-)	(+)	(+)	(+)	(+)	-	Small and single blastoconidia with pseudohyphae and true hyphae	<i>Candida tropicalis</i>	6	15.0
5	Baby Purple	(-)	(+)	(-)	(-)	(-)	(-)	(+)	-	Yeast cells, without pseudohyphae	<i>Candida glabrata</i>	5	12.5
6	Pink	Variable	(+)	(-)	(-)	(-)	(-)	(-)	-	Pseudohyphae with oval to elongated blastoconidia which forms cross-matchsticks or resembles trees	<i>Candida krusei</i>	5	12.5
7	White-Pink	(-)	(+)	(-)	(+)	(-)	(+)	(+)	-	Blastoconidia are in small groups with short pseudohyphae and relatively few yeast cells	<i>Candida guillemontii</i>	0	0.0
Total Species											40	100.0	

Glu = glucose, Lac = lactose, Suc = sucrose, Mal = Maltose, Gal = Galactose, Tre = Trehalose, Temp = temperature.

One subject can have more than one *Candida* isolate that grew.

Table 4 Resistance of each isolate of *Candida* species to ketoconazole antifungals

S. No.	Species	Total	%	Ketoconazole					
				S	%	I	%	R	%
1	<i>Candida albicans</i>	23	57.5%	23	100	0	0	0	0
2	Non- <i>albicans Candida</i> :	17	42.5%	11	65	4	23	2	12
	- <i>Candida dubliniensis</i>	0	0.0%	0	0	0	0	0	0
	- <i>Candida glabrata</i>	5	12.5%	4	80	1	20	0	0
	- <i>Candida guillemontii</i>	0	0.0%	0	0	0	0	0	0
	- <i>Candida krusei</i>	5	12.5%	2	40	3	60	0	0
	- <i>Candida parapsilosis</i>	1	2.5%	1	100	0	0	0	0
	- <i>Candida tropicalis</i>	6	15.0%	4	66	0	0	2	34
	TOTAL	40	100.0%	34	85	4	10	2	5

The sensitivity test results of isolates on ketoconazole drugs showed that the number of *Candida* species sensitive to ketoconazole was 34(85%), while the number of *Candida* species resistant to ketoconazole was 2(5%). All 23 *C. albicans* (100%) and 11(64%) of the *Candida non-albicans* species were sensitive to ketoconazole. Of all *Candida non-albicans* species, 4(23%) were intermediate and only 2(13%) were resistant to ketoconazole (Table 4).

DISCUSSION:

Demographic profiles of the study participants showed that most of them are in the adult group. Data from Indonesian Ministry of Health in 2016 found that more than 50% of HIV/AIDS patients were young adult and within productive age groups ranging from 25-49 years old.¹⁵ Adults in productive age are mostly sexually active and more likely to do unsafe sex which predispose themselves for HIV transmission.¹⁶ Education level showed that 3 people (13%) never went to school and 7 patients (31%) graduated from elementary/junior high school. Occupational backgrounds of participants in this study showed that 11 patients (48%) are unemployed. HIV/AIDS patients from low educational and socioeconomic backgrounds may have a very limited access to oral health services. This reduce their ability to maintain the health of the oral cavity so they easily experience diseases in the oral cavity. Patients with HIV/AIDS during the course of their illness will also experience various kinds of opportunistic infections that affect the quality of life, including losing their job.^{8,17}

The most prevalent HIV transmission in this study was from heterosexual intercourse, as found in 57% patients. This is similar to the general picture of HIV/AIDS in East Java where the main transmission of HIV/AIDS, especially through heterosexuals, was 69.6% while transmission through needle from drug users were 21.9%.¹⁸ OC patients with HIV/AIDS in this study had more than one type of complaint. The most common major complaint is white patches in the oral cavity (100%) with a diagnosis of pseudomembranous OC. The results of the same study were carried out in India in 2013 where pseudomembranous OC was found in

76.2% research subjects.¹⁹ The subjects in this study showed that 19 of them (83%) had received ARV therapy, while 4 of them (17%) had not received ARV. Although the incidence of opportunistic infections including OC have decreased with ARV therapy, OC remains a common problem in HIV/AIDS patients on active ARV therapy. This is because of the presence of other factors such as such as high virulence of *Candida* species and combinations of *Candida albicans* and non-*albicans* species infection, which further make OC to be recurrent and difficult to treat.²⁰ Research by Moges in Ethiopia in 2013 showed that OC was found in 58.7% patients who were not on ARV therapy, but only 41.3% patients who received ARV therapy were found to have OC.¹

Identification of *Candida* species in this study used a combination of *Candida* CHROMagar, Cornmeal and carbohydrate tests. Identification of species by this method also has advantages especially for areas with limited facilities, and this method also has good accuracy compared to the latest methods such as Vitek-II which are more expensive.²¹ Different *Candida* species grown in CHROMagar will produce colonies with distinct colors.²² In this study, 23 research subjects and 40 *Candida* isolates were obtained. In 10 research subjects, growth of more than one species of *Candida* was found. The most common causes of OC in patients with HIV/AIDS infection in this study were *C. albicans* which was 57.5%, whereas infection from *Candida non-albicans* in this study was 42.5%, sequentially consisting of *C. tropicalis*, *C. glabrata*, *C. krusei* and *C. parapsilosis* species. A study by Reza in 2017 also showed that *C. albicans* is still the main cause of OC.⁸ Similar finding was also found in various international studies that *C. albicans* was the main cause in OC patients with HIV/AIDS.¹

In this study, a spectrum of changes in the causes of OC was found. Even though *C. albicans* was still more common but *Candida non-albicans* began to increase. Factors such as recurrent OC were considered to cause differences in *Candida* species and predispose to shift into *Candida non-albicans* species.¹ This was thought to be due to exposure to antifungals in patients with

recurrent OC. Most of the patients in this study have history of both systemic and topical antifungal therapy. Previous antibiotics and antifungal therapy have been related to the increase in the number of *Candida non-albicans* colonies in the oral cavity of individuals infected with HIV/AIDS.^{1,21,23} Prior antifungal therapies may cause selective pressure and results in replacement of *C. albicans* by *C. glabrata*.¹ The broad-spectrum antibiotics has shown to be able to change normal flora bacteria by killing bacteria and increasing the proliferation of *Candida* species.^{24,25} A study conducted by Mushi in 2016 in Tanzania stated that the use of previous antibiotics is a statistically significant factor in increasing colonization of *Candida non-albicans* species.²⁴ In addition, in the course of advanced HIV/AIDS, extensive fungal colonization was also found.¹⁷ Presence of *Candida non-albicans* species can be a concern to public health because this species is often associated with resistance to azole antifungals and will be difficult to treat.²⁴

All *Candida* samples were tested for sensitivity to ketoconazole by the disk diffusion method. In this study, the number of *Candida* species sensitive to ketoconazole is 34 samples (85%) while the number of resistant *Candida* species is in 2% samples. All 23 *C. albicans* (100%) were sensitive to ketoconazole and 11(64%) of the *Candida non-albicans* species sensitive to ketoconazole, while 4(23%) were intermediate and only 2(13%) were resistant to ketoconazole. Both of ketoconazole-resistant *Candida* species were *C. tropicalis*. The results above are in accordance with research conducted by Anna in 2012 in Cameroon which is also a pandemic area for HIV/AIDS. Fluconazole is a first-line therapy in OC patients with HIV/AIDS and also given free of charge in the country. The widespread use increased the incidence of fluconazole resistance. In that study most of the *C. albicans* species (80%) were sensitive to ketoconazole. The study recommended ketoconazole as the drug of choice in OC cases caused by fluconazole-resistant *C. albicans* species.²⁶

Identification and sensitivity testing of causative *Candida* species in OC patients with HIV/AIDS should be investigated periodically to look at the changes in the spectrum of the species and to reevaluate and update the guidelines for OC therapy. This study showed a spectrum of change in the causes of OC in which *Candida non-albicans* began to increase although *C. albicans* was still more common. Sensitivity testing showed that all *C. albicans* and 64% of the *Candida non-albicans* species were sensitive to ketoconazole. All of the ketoconazole-resistant *Candida* species were *C. tropicalis*. Thus, ketoconazole can be recommended as a treatment option for OC patients with HIV/AIDS due to the high sensitivity of both *C. albicans* and *non-albicans*

to this drug.

ACKNOWLEDGEMENT:

The authors are grateful to Pepy Dwi Indraswari, Dr., M. Si., Sp. MK, from the Department, Functional Medical Staff of Microbiology, Dr. Soetomo General Hospital, Surabaya Indonesia.

CONFLICT OF INTEREST:

The authors declare no conflict of interest.

REFERENCES:

1. Moges B, Bitew A, and Shewaamare A. Spectrum and the in vitro antifungal susceptibility pattern of yeast isolates in Ethiopian HIV patients with oropharyngeal candidiasis. *International Journal of Microbiology*. 2016; 2016: 1-8.
2. Varshan R, Gopinath P. Characterization and biofilm detection among clinically important *Candida* species. *Research Journal of Pharmacy and Technology*. 2016; 9(9): 1375-1378
3. Sangamithra V, Verma R, Sengottuvelu S, Sumathi R. *Candida* infections of the genitourinary tract. *Research Journal of Pharmacy and Technology*. 2013; 6(10): 1110-1115
4. Charyulu RN, Devi PP, Jose J, Shetty AV. Formulation and evaluation of mucoadhesive oral gel containing miconazole nitrate for oral candidiasis. *Research Journal of Pharmacy and Technology*. 2013; 6(11): 1251-1257
5. Kundu RV, and Garg A. Yeast infection: tinea (pityriasis) versicolor, Malassezia (pityrosporum) folliculitis. In Fitzpatrick's *Dermatology in General Medicine*. Edited by Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell D, and Wolff K. McGraw-Hill, New York. 2012; 8th ed: pp. 2298-2311.
6. Jangir N, Bakshi S, Vyas N. Isolation and detection of *Aspergillus* and *Candida* species in sputum of HIV positive patients and it correlate with CD4. *Research Journal of Pharmacy and Technology*. 2012; 5(6): 785-788
7. Uihlein L, Saavedra AP, and Johnson RA. Cutaneous manifestations of human immunodeficiency virus disease. In Fitzpatrick's *Dermatology in General Medicine*. Edited by Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell D, and Wolff K. McGraw-Hill, New York. 2012; 8th ed: pp. 4574-4575.
8. Reza NR, Sugiman T, and Basuki S. Uji kepekaan in vitro flukonazol terhadap spesies *Candida* penyebab kandidiasis oral pada pasien HIV/AIDS dengan Vitek II. *BIKKK - Berkala Ilmu Kesehatan Kulit dan Kelamin - Periodical of Dermatology and Venereology*. 2017; 29(3): 234-242.
9. Ahmed LT. Genotyping and antifungal susceptibility of *C. albicans* isolated from infected woman. *Research Journal of Pharmacy and Technology*. 2019; 12(11): 5171-5176
10. Suyoso S, Ervianti E, and Barakbah J. Kandidiasis mukosa. In *Panduan praktik klinis SMF Ilmu Kesehatan Kulit dan Kelamin RSUD Dr. Soetomo, Surabaya*. Edited by Suyoso S, Ervianti E, and Barakbah J. SMF. Ilmu Kesehatan Kulit dan Kelamin RSUD. Dr. Soetomo, Surabaya. 2014; pp.95-97.
11. Wahyuli HN, Suyoso S, and Prakoeswa CRS. Manifestasi klinis dan identifikasi spesies penyebab kandidiasis oral pada pasien HIV/AIDS di RSUD dr. Soetomo Surabaya. *BIKKK - Berkala Ilmu Kesehatan Kulit dan Kelamin - Periodical of Dermatology and Venereology*. 2010; 22: 11-6.
12. Sobel JD, and Akins RA. The role of resistance in *Candida* infections: epidemiology and treatment. In *Antimicrobial Drug Resistance*. Edited by Mayers D, Sobel JD, Ouellette M, Kaye KS, and Marchaim D. Springer International Publishing; Cahm. 2017; 2nd ed: pp. 1075-1097
13. Pandey M, Sharma S, Mishra SK. Evaluation of blood stream infection caused by *Candida albicans*. *Research Journal of Pharmacy and Technology*. 2014; 6(3): 139-140
14. Kadry AA, El-Ganiny AM, El-Baz AM. Comparison of methods

- used in identification of *Candida albicans*. *Research Journal of Pharmacy and Technology*. 2018; 11(3): 1164-1168
15. Infodatin Pusat Data dan Informasi Kementerian Kesehatan RI. Situasi penyakit HIV AIDS di Indonesia. Available from: URL: <http://www.pusdatin.kemkes.go.id>
 16. Yowel, Waluyo A, and Kuntarti K. Umur orang dengan HIV AIDS (ODHA) berhubungan dengan tindakan pencegahan penularan HIV. *Jurnal Keperawatan Indonesia*. 2016; 19(3):200-7.
 17. Bajomo AS, Ayo-Yusuf OA, and Rudolph MJ, Tsotsi NM. Impact of oral lesions among South African adult with HIV/AIDS on oral health-related quality of life. *Journal of Dental Sciences*. 2013; 8: 412-7.
 18. Dinas Kesehatan Provinsi Jawa Timur. Profil kesehatan provinsi Jawa Timur tahun 2013. Available from: URL: http://www.depkes.go.id/resources/download/profil/PROFIL_KES_PROVINSI_2013/15_Prov_Jatim_2013.pdf
 19. Maurya V, Srivastava A, Mishra J, Gaiind R, Marak RSK, Tripathi AK, et al. Oropharyngeal candidiasis and *Candida* colonization in HIV positive patients in northern India. *The Journal of Infection in Developing Countries*. 2013; 7(8): 608-13
 20. Patel PK, Erlandsen JE, Kirkpatrick WR, Berg DK, Westbrook SD, Loudon C, et al. The changing epidemiology of oropharyngeal candidiasis in patients with HIV/AIDS in the era of antiretroviral therapy. *AIDS Research and Treatment*. 2012; 262471
 21. Sariguzel FM, Berk E, Koc A, Sav H, and Aydemir G. Evaluation of CHROMagar *Candida*, Vitek 2 YST and Vitek MS for identification of *Candida* strains isolated from blood cultures. *Le Infezioni in Medicina*. 2015; 23(4): 318-22
 22. Tamizh PT, Gopinath P. Differentiation of *Candida dubliniensis* on CHROM agar and Pal's agar. *Research Journal of Pharmacy and Technology*. 2016; 9(12): 2150-2154
 23. Anuradha V, Praveena A, Habeeb SKM, Madan. Identification of drug targets through mutational analysis of drug resistance genes in *Candida albicans*. *Research Journal of Pharmacy and Technology*. 2013; 6(3): 267-277
 24. Mushi MF, Mtemisika CI, Bader O, Bii C, Mirambo MM, Gro U, et al. High oral carriage of non-*albicans* *Candida* spp. among HIV-infected individuals. *International Journal of Infectious Diseases*. 2016; 49: 185-8
 25. Prasanna GE, Gopinath P. Characterization and detection of biofilm among clinical isolates of *Candida* species by tube method. *Research Journal of Pharmacy and Technology*. 2016; 9(12): 2109-2112
 26. Njunda AL, Nsagha DS, Assob JCN, Kamga HL, and Teyim P. In vitro antifungal susceptibility patterns of *Candida albicans* from HIV and AIDS patients attending the Nylon Health District Hospital in Douala, Cameroon. *Journal of Public Health in Africa*. 2012; 3: 1-4